← Leaderboards
Chi T. Viet
Loma Linda University
$4,561,149
Attributed
$5,256,117
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2021–25$2M$1.5M$1M$500K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,256,117 · 3
By mechanism
R01$4,391,037 · 2
K23$865,080 · 1
Top collaborators
- Bradley E Aouizerat2 shared
Others in their field
Other Emerging Leaders on “Malignant Neoplasms”
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
- Leonard Freedmand · Leidos Biomedical Research, Inc.$108,968,336
- Beverly Hayes · Leidos Biomedical Research, Inc.$98,336,166
- Martha Hering · Westat, Inc.$57,098,843
Research focus
Malignant NeoplasmsEpigenetic ProcessTissuesProspectiveBiological MarkersClinical ResearchMolecularGenesMalignant Mouth NeoplasmEnrollmentMethylationSurgeonSeriesTrainingDesignProspective StudiesPrognostic ValuePrognostic MarkerMorbidity - Disease RateMolecular MarkerMouth Squamous Cell CarcinomaProspective CohortHistologicHigh Risk
Grant awards (11)
The REASON Score: An Epigenetic And Clinicopathologic Score to Predict Risk of Poor Survival in Early Stage Oral Squamous Cell Carcinoma Patients$727,669
R01 · FY2025 · DE · contact PI
PROSPECT: Premalignant Oral Lesions Pathology and Epigenetic Risk Prediction Tool$679,280
R01 · FY2025 · CA · contact PI
Clinical study to evaluate the methylation signature of head and neck squamous cell carcinoma pain$173,016
K23 · FY2025 · DE · contact PI
The REASON Score: An Epigenetic And Clinicopathologic Score to Predict Risk of Poor Survival in Early Stage Oral Squamous Cell Carcinoma Patients$722,524
R01 · FY2024 · DE · contact PI
PROSPECT: Premalignant Oral Lesions Pathology and Epigenetic Risk Prediction Tool$710,656
R01 · FY2024 · CA · contact PI
Clinical study to evaluate the methylation signature of head and neck squamous cell carcinoma pain$173,016
K23 · FY2024 · DE · contact PI
The REASON Score: An Epigenetic And Clinicopathologic Score to Predict Risk of Poor Survival in Early Stage Oral Squamous Cell Carcinoma Patients$748,379
R01 · FY2023 · DE · contact PI
Clinical study to evaluate the methylation signature of head and neck squamous cell carcinoma pain$173,016
K23 · FY2023 · DE · contact PI
The REASON Score: An Epigenetic And Clinicopathologic Score to Predict Risk of Poor Survival in Early Stage Oral Squamous Cell Carcinoma Patients$802,529
R01 · FY2022 · DE · contact PI
Clinical study to evaluate the methylation signature of head and neck squamous cell carcinoma pain$173,016
K23 · FY2022 · DE · contact PI
Clinical study to evaluate the methylation signature of head and neck squamous cell carcinoma pain$173,016
K23 · FY2021 · DE · contact PI